|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated
advanced non-small-cell lung cancer. N Engl J Med. 378:113–125.
2018. View Article : Google Scholar
|
|
5
|
Dai C, Shen J, Ren Y, Zhong S, Zheng H, He
J, Xie D, Fei K, Liang W, Jiang G, et al: Choice of surgical
procedure for patients eith mon-dmall-vell lung vancer ≤1 cm or
>1 to 2 cm smong lobectomy, segmentectomy, and wedge resection:
A Population-based study. J Clin Oncol. 34:3175–3182. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hemminki A, Markie D, Tomlinson I,
Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M,
Höglund P, et al: A serine/threonine kinase gene defective in
Peutz-Jeghers syndrome. Nature. 391:184–187. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network:
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mihaylova MM and Shaw RJ: The AMPK
signalling pathway coordinates cell growth, autophagy and
metabolism. Nat Cell Biol. 13:1016–1023. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wodarz A and Näthke I: Cell polarity in
development and cancer. Nat Cell Biol. 9:1016–1024. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carretero J, Shimamura T, Rikova K,
Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA,
McNamara KL, Brandstetter KA, et al: Integrative genomic and
proteomic analyses identify targets for Lkb1-deficient metastatic
lung tumors. Cancer Cell. 17:547–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Contreras CM, Akbay EA, Gallardo TD,
Haynie JM, Sharma S, Tagao O, Bardeesy N, Takahashi M, Settleman J,
Wong KK, et al: Lkb1 inactivation is sufficient to drive
endometrial cancers that are aggressive yet highly responsive to
mTOR inhibitor mono-therapy. Dis Model Mech. 3:181–193. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamamoto T, Gotoh M, Sasaki H, Terada M,
Kitajima M and Hirohashi S: Molecular cloning and initial
characterization of a novel fibrinogen-related gene, HFREP-1.
Biochem Biophys Res Commun. 193:681–687. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rijken DC, Dirkx SP, Luider TM and Leebeek
FW: Hepatocyte-derived fibrinogen-related protein-1 is associated
with the fibrin matrix of a plasma clot. Biochem Biophys Res
Commun. 350:191–194. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nayeb-Hashemi H, Desai A, Demchev V,
Bronson RT, Hornick JL, Cohen DE and Ukomadu C: Targeted disruption
of fibrinogen like protein-1 accelerates hepatocellular carcinoma
development. Biochem Biophys Res Commun. 465:167–173. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weinstein JN, Collisson EA, Mills GB, Shaw
KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM;
Cancer Genome Atlas Research Network: The Cancer Genome Atlas
Pan-Cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets - update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar
|
|
17
|
Schabath MB, Welsh EA, Fulp WJ, Chen L,
Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, et
al: Differential association of STK11 and TP53 with KRAS
mutation-associated gene expression, proliferation and immune
surveillance in lung adenocarcinoma. Oncogene. 35:3209–3216. 2016.
View Article : Google Scholar :
|
|
18
|
Girard L, Rodriguez-Canales J, Behrens C,
Thompson DM, Botros IW, Tang H, Xie Y, Rekhtman N, Travis WD,
Wistuba II, et al: An expression signature as an aid to the
histologic classification of non-small cell lung cancer. Clin
Cancer Res. 22:4880–4889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan TD, Black D, Bannon PG and McCaughan
BC: Systematic review and meta-analysis of randomized and
nonrandomized trials on safety and efficacy of video-assisted
thoracic surgery lobectomy for early-stage non-small-cell lung
cancer. J Clin Oncol. 27:2553–2562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Na F, Wang J, Li C, Deng L, Xue J and Lu
Y: Primary tumor standardized uptake value measured on
F18-Fluorodeoxyglucose positron emission tomography is of
prediction value for survival and local control in non-small-cell
lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol.
9:834–842. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rossi A, Chiodini P, Sun JM, O'Brien ME,
von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, et
al: Six versus fewer planned cycles of first-line platinum-based
chemotherapy for non-small-cell lung cancer: A systematic review
and meta-analysis of individual patient data. Lancet Oncol.
15:1254–1262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blumenthal GM, Zhang L, Zhang H,
Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P
and Pazdur R: Milestone analyses of immune checkpoint inhibitors,
targeted therapy, and conventional therapy in metastatic non-small
cell lung cancer trials: A Meta-analysis. JAMA Oncol.
3:e1710292017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kulkarni S, Vella E, Coakley N, Cheng S,
Gregg R, Ung Y and Ellis PM: The use of systemic treatment in the
maintenance of patients with non-small cell lung cancer: A
systematic review. J Thorac Oncol. 11:989–1002. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zer A, Ding K, Lee S, Goss G, Seymour L,
Ellis P, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, et al:
Pooled analysis of the prognostic and predictive value of KRAS
mutation status and mutation subtype in patients with non-small
cell lung cancer treated with epidermal growth factor receptor
tyrosine kinase inhibitors. J Thorac Oncol. 11:312–323. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qiu F, Yang L, Ling X, Yang R, Yang X,
Zhang L, Fang W, Xie C, Huang D, Zhou Y, et al: Sequence variation
in mature MicroRNA-499 confers unfavorable prognosis of lung cancer
patients treated with platinum-based chemotherapy. Clin Cancer Res.
21:1602–1613. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang H, Wang S, Xiao G, Schiller J,
Papadimitrakopoulou V, Minna J, Wistuba II and Xie Y: Comprehensive
evaluation of published gene expression prognostic signatures for
biomarker-based lung cancer clinical studies. Ann Oncol.
28:733–740. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shackelford DB and Shaw RJ: The LKB1-AMPK
pathway: Metabolism and growth control in tumour suppression. Nat
Rev Cancer. 9:563–575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sanchez-Cespedes M, Parrella P, Esteller
M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG and Sidransky
D: Inactivation of LKB1/STK11 is a common event in adenocarcinomas
of the lung. Cancer Res. 62:3659–3662. 2002.PubMed/NCBI
|
|
32
|
Fang R, Zheng C, Sun Y, Han X, Gao B, Li
C, Liu H, Wong KK, Liu XY, Chen H, et al: Integrative genomic
analysis reveals a high frequency of LKB1 genetic alteration in
Chinese lung adenocarcinomas. J Thorac Oncol. 9:254–258. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Calles A, Sholl LM, Rodig SJ, Pelton AK,
Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM,
et al: Immunohistochemical loss of LKB1 is a biomarker for more
aggressive biology in KRAS-mutant lung adenocarcinoma. Clin Cancer
Res. 21:2851–2860. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han
X, Shen L, Liu XY, Pao W, Chen H, et al: Spectrum of LKB1, EGFR,
and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol.
5:1130–1135. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shackelford DB, Abt E, Gerken L, Vasquez
DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS,
et al: LKB1 inactivation dictates therapeutic response of non-small
cell lung cancer to the metabolism drug phenformin. Cancer Cell.
23:143–158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Demchev V, Malana G, Vangala D, Stoll J,
Desai A, Kang HW, Li Y, Nayeb-Hashemi H, Niepel M, Cohen DE, et al:
Targeted deletion of fibrinogen like protein 1 reveals a novel role
in energy substrate utilization. PLoS One. 8:e580842013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zou Z, Cai Y and Chen Y, Chen S, Liu L,
Shen Z, Zhang S, Xu L and Chen Y: Bone marrow-derived mesenchymal
stem cells attenuate acute liver injury and regulate the expression
of fibrinogen-like-protein 1 and signal transducer and activator of
transcription 3. Mol Med Rep. 12:2089–2097. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang H, Meyer CA, Fei T, Wang G, Zhang F
and Liu XS: A systematic approach identifies FOXA1 as a key factor
in the loss of epithelial traits during the
epithelial-to-mesenchymal transition in lung cancer. BMC Genomics.
14:6802013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Çeliktas M, Tanaka I, Tripathi SC,
Fahrmann JF, Aguilar-Bonavides C, Villalobos P, Delgado O, Dhillon
D, Dennison JB, Ostrin EJ, et al: Role of CPS1 in cell growth,
metabolism and prognosis in LKB1-inactivated lung adenocarcinoma. J
Natl Cancer Inst. 109:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Okon IS, Coughlan KA, Zhang C, Moriasi C,
Ding Y, Song P, Zhang W, Li G and Zou MH: Protein kinase LKB1
promotes RAB7-mediated neuropilin-1 degradation to inhibit
angiogenesis. J Clin Invest. 124:4590–4602. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Roy BC, Kohno T, Iwakawa R, Moriguchi T,
Kiyono T, Morishita K, Sanchez-Cespedes M, Akiyama T and Yokota J:
Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of
human lung cancer cells. Lung Cancer. 70:136–145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shaw RJ, Kosmatka M, Bardeesy N, Hurley
RL, Witters LA, DePinho RA and Cantley LC: The tumor suppressor
LKB1 kinase directly activates AMP-activated kinase and regulates
apoptosis in response to energy stress. Proc Natl Acad Sci USA.
101:3329–3335. 2004. View Article : Google Scholar : PubMed/NCBI
|
